Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation

Conditional marketing authorization (CMA) facilitates timely access to new drugs for illnesses with unmet clinical needs, such as late graft failure after kidney transplantation. Late graft failure remains a serious, burdensome, and life-threatening condition for recipients. This article has been de...

Descripción completa

Detalles Bibliográficos
Autores principales: Naesens, Maarten, Loupy, Alexandre, Hilbrands, Luuk, Oberbauer, Rainer, Bellini, Maria Irene, Glotz, Denis, Grinyó, Josep, Heemann, Uwe, Jochmans, Ina, Pengel, Liset, Reinders, Marlies, Schneeberger, Stefan, Budde, Klemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163307/
https://www.ncbi.nlm.nih.gov/pubmed/35669977
http://dx.doi.org/10.3389/ti.2022.10137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163307/
https://www.ncbi.nlm.nih.gov/pubmed/35669977
http://dx.doi.org/10.3389/ti.2022.10137

Ejemplares similares